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Since the identiﬁcation of HIV and HCV much progress has been made in the understanding of their life cycle and interaction
with the host immune system. Despite these viruses markedly diﬀer in their virological properties and in their pathogenesis, they
share many common features in their immune escape and survival strategy. Both viruses have developed sophisticated ways to
subvert and antagonize host innate and adaptive immune responses. In the last years, much eﬀort has been done in the study
of the AIDS pathogenesis and in the development of eﬃcient treatment strategies, and a fatal infection has been transformed
in a potentially chronic pathology. Much of this knowledge is now being transferred in the HCV research ﬁeld, especially in the
developmentofnewdrugs,althoughabigdiﬀerencestillremainsbetweentheoutcomeofthetwoinfections,beingHCVeradicable
after treatment, whereas HIV eradication remains at present unachievable due to the establishment of reservoirs. In this review, we
presentcurrentknowledgeoninnateandadaptiveimmunerecognitionandactivationduringHIVandHCVmono-infectionsand
evasion strategies. We also discuss the genetic associations between components of the immune system, the course of infection,
and the outcome of the therapies.
1.Introduction
1.1. Human Immunodeﬁciency Virus Infection. Human im-
munodeﬁciency virus (HIV) is a retrovirus of the Lentiviri-
dae family. This positive strand RNA virus infects speciﬁc
cell populations of the immune system through its receptor
speciﬁcity. At present, more than 33 million people are
infected with HIV. HIV infection is characterized by an acute
and a chronic phase, possibly leading to AIDS. Immediately
after infection the viral load increases with exponential
growth kinetics and CD4+ T cells rapidly decline [1, 2]. The
peakofthisgrowthcurvecoincideswiththeonsetofastrong
host immune response resulting in decreasing viral load and
increasing number of circulating virus-speciﬁc CD4+ T cells.
Then, the acute phase of HIV infection is accompanied by
a selective and dramatic depletion of CD4+CCR5+ memory
T cells predominantly from mucosal surfaces. This loss is
largely irreversible and ultimately leads to the failure of
the host immune defenses to clear the infection [3, 4].
This allows HIV to establish life-long latency and chronic
infection.
Over the chronic phase of infection, the viral load
remains stable, whereas CD4+ T cell levels gradually decline
[5]. The chronic phase is clinically latent, but eventually
without therapeutic intervention, the infection progresses to
the symptomatic phase characterized by increased viral load
and rapidly decreasing CD4+ T cell and also CD8+ Tc e l l
levels, making patients prone to opportunistic infections [6].
During HIV infection, both innate and adaptive immune
responses are raised, but are insuﬃcient or too late to elimi-
natethevirus.Additionally,theverysamecellsandresponses
aimed at eliminating the virus seem to play deleterious roles
by driving chronic immune activation that plays a central
part in immunopathogenesis and progression to AIDS [7, 8].
1.2. Hepatitis C Virus Infection. Hepatitis C virus (HCV) is
a positive-stranded RNA virus belonging to the Flaviviridae
family. Six major HCV genotypes have been identiﬁed and
more than 100 subtypes have been identiﬁed through the
world on the basis of molecular relatedness of conserved and
non-conserved regions. Furthermore, several distinct but2 Advances in Virology
closely related HCV sequences coexist within each infected
individual. These are referred to as quasi-species and reﬂect
the high replication rate of the virus and the lack of a proof-
reading capacity of the RNA-dependent RNA polymerase.
More than 170 million people worldwide are chronically
infected with HCV, which is a major cause of chronic hep-
atitis, cirrhosis, and hepatocellular carcinoma. Individuals
infected with HCV have two possible outcomes of infection,
clearance or persistent infection, determined by a complex
set of virus-host interactions [9].
The majority of episodes of primary HCV infection are
asymptomatic and infection is often detected incidentally at
the time of routine health examinations or when donating
blood. After initial exposure to HCV, 54–80% of infected
person develop persistent viremia despite the generation
of HCV-speciﬁc antibodies detected by ELISA and HCV-
speciﬁc cellular immune responses [10–12]. This indicates
that anti-viral immune response is functionally ineﬀective in
the majority of exposed individuals. A correlation between
syntomatic disease and viral clearance has been reported,
possibly due to a more vigorous immune response, which
alsoresultsingreaterliverinjury[11].InchronicHCVinfec-
tion, the liver is typically inﬁltrated by mononuclear cells
including CD4+ and CD8+ T lymphocytes, B lymphocytes,
as well as natural killer (NK) cells (CD56+CD3−)a n dN KT
cells (CD56+CD3+).
Knowledge of the early immune response at the site
of infection derives from recent studies on experimentally
infected chimpanzees [13, 14], the only animal model used
to study immune responses during the natural course of
infection. Research into viral-host protein interactions has
recently progressed rapidly with the development of an
eﬀective in vitro HCV culture system, which was previously
unavailable [15–18].
1.3. HIV/HCV Coinfection. Infection with HCV is the most
common co-infection in people with HIV, and HCV is cate-
gorized as an HIV-related opportunistic illness [19]. Com-
plications related to HIV/HCV co-infection are becoming
an increasingly important medical issue. Owing to shared
modes of transmission, as many as 30 to 40% of people
with HIV may also be co-infected with HCV. HCV is
approximately 10 times more infectious than HIV through
percutaneous blood exposures. Though HCV is less likely
than HIV to be transmitted sexually or from mother to baby,
some studies have shown that the risk of sexual or perinatal
(mother to baby) HCV transmission is higher in HIV+
individuals.Moreover,HIV/HCVco-infectionisasigniﬁcant
problem among injection drug users (IDUs) as well as
men who have sex with men (MSMs). The introduction
in the mid-1990s of highly active antiretroviral therapy
(HAART) for HIV has caused a sharp drop in the number
of deaths from AIDS. This means that people with HIV
are living longer. Therefore, if they are co-infected, the
complications from HCV have more time to develop [20].
These complications (cirrhosis, liver cancer, end-stage liver
disease) generally develop over 20–30 years. Liver disease
from HCV is now the leading non-AIDS cause of death in
the U.S. in co-infected individuals with HIV.
Thewaysinwhichco-infectionwithHIVandHCVaﬀect
the body are still poorly understood. Most studies indicate
that HIV can worsen hepatitis C. HIV/HCV co-infection
has been associated with a faster rate of hepatitis C disease
progression, higher HCV viral loads, and a greater risk of
developing severe liver damage. The impact of HCV on HIV
disease is less clear, but a majority of studies suggest that
hepatitisCdoesnotaccelerateHIVdiseaseprogression.Hep-
atitis C can aﬀect HIV treatment by increasing the frequency
of liver toxicity related to antiretroviral drugs. There is also
the potential for interactions between drugs used to treat
HIV and HCV infections. However, with careful medical
monitoring, many co-infected people can be successfully
treated for both HIV and HCV. Some experts believe it is
better to begin HIV treatment ﬁrst in order to control HIV
replication and increase the CD4 count, since hepatitis C
treatment works better in people with stronger immune
systems [21]. Some research suggest that even after starting
HIV treatment, CD4 counts do not increase as rapidly in co-
infected people as in people with HIV alone. However, in
people with early-stage HIV disease and advanced hepatitis
C, it may be better to start HCV treatment ﬁrst, so the
liver can more easily handle HIV drugs since many HIV
medications are metabolized by the liver and some can cause
liver toxicity (hepatotoxicity).
2. AntiviralImmuneResponse
2.1. Innate Immune Responses. The innate immune system
constitutes the ﬁrst line of defense against invading patho-
gens and it functions during the early phase of infection,
before the development of speciﬁc adaptive immunity. It is
based on epithelial barriers, the complement system, and
cells with phagocytotic and antigen presenting properties,
such as granulocytes, macrophages, monocytes, Langerhans
cells, dendritic cells (DCs), NK cells, and γδ T cells [22,
23]. It plays a part in early restriction of the virus and in
shaping the adaptive immune response, but at the same time
participates in the establishment and spread of infection.
DCs and NK cells are vital mediators of the innate immune
system and promote the development of adaptive immune
responses [24]. DCs are of pivotal importance because they
are among the earliest targets of HIV and are crucial for
activating and conditioning virus-speciﬁc T cells, a process
that is largely inﬂuenced by the preceding innate immune
response[25].MyeloidDCs(mDC)sareprofessionalantigen
presenting cells present in blood, skin, and mucosal tissues,
whereas plasmacytoid DCs (pDCs) are located in blood and
secondary lymphoid organs and play important roles in
innate immune responses to viruses through the production
of type I Interferons (IFN) [26].
Unlike adaptive immunity, the innate immune cells do
not use T cell receptors; they are not major histocompati-
bility complex restricted; and they apparently lack memory,
which is essential in vaccination. An early non speciﬁc
protective response may limit microbial replication and
dissemination, and allow adaptive immunity suﬃcient time
to mount an eﬀective protective response.Advances in Virology 3
Innate immune responses to viral infections generally
feature the induction of both cellular responses via NK
cells,andantiviralproteins,notablyIFN-α andIFN-β,which
generate an antiviral state [27]. The recent discovery of
a fundamental pathogen recognition system which boosts
innate immunity and drives the induction of type I IFN
has dramatically advanced understanding of host responses
to viral infection [28]. This system is based on pathogen-
associated molecular patterns (PAMPs), which are recog-
nized by speciﬁc PAMP receptors expressed in the host cell,
initiating signals that ultimately induce the expression of
antiviral eﬀectors genes [29].
The receptors of the innate immune system that recog-
nize PAMPs are called pattern-recognition receptors (PRRs).
Among PRRs, the family of Toll-like receptors (TLRs) have
been studied most extensively. TLRs are membrane bound
receptors and 10 diﬀerent TLRs have been identiﬁed in
humans. Of those, viral recognition is primarily mediated by
TLR9 recognizing DNA, as well as by TLRs 7/8 and TLR3
sensing single-stranded (ss) RNA and doublestranded (ds)
RNA, respectively [30, 31]. In addition, C-type lectin recep-
tors, such as DC-SIGN, Dectin-1, and mannose receptor,
have emerged as cell surface PRRs that play important roles
in induction of immune responses against various pathogens
[32]. DC-SIGN, in particular, has been attributed essential
roles as an adhesion receptor, in mediating interactions
between DCs and T cells, and as a PRR inducing speciﬁc
immune responses [33].
2.1.1. HIV. The innate immune cells involved in protection
of HIV infection are Langerhans cells in vaginal and foreskin
epithelia [34, 35]; γδ+ T cells in rectal and vaginal epithelia;
and macrophages, DCs, and NK cells in the subepithelial
tissues.
Interestingly, opposing roles for mDCs and pDCs in
HIV infection have been described [36]. Whereas mDCs
enhance HIV infection through capture and subsequent
transmission of the virus, pDCs inhibit HIV replication in
T cells through the antiviral activities of IFN-α [37]. Since
pDCs are the major producers of type I IFN, it has been
suggested that abnormal migration and localization patterns
of this important cell type may be a key defense strategy of
HIV [38].
NK cells play a major role in preventing the early
spread of viruses by producing cytokines and directly killing
infected cells. NK cells may be crucial for early control of
HIV infection and can have important roles in editing the
function of DCs, thereby aﬀecting their ability to prime
antiviral eﬀector T cells. They kill cells by releasing perforin
and granzyme that cause the target cell to die by apoptosis.
NK cells do not require activation in order to kill target cells,
do not express T cell antigen receptors (TCR), whereas
they express Fc receptor (FcR) to lyse cells through either
to activate or to suppress their cytolytic activity. In general,
NK receptors recognise missing self (MHC), induced self, or
modiﬁed self (stress signals) proteins as their ligands [33].
As in NK cells, γδ T cells express the inhibitory receptors
KIR, which recognize major histocompatibility complex
class I molecules and inhibit cytotoxic responses [38]. The
N K G 2 Da c t i v a t i n gr e c e p t o r sa r ea l s of o u n do nγδ T cells,
and they recognize the human MHC class I chain-related
proteins MICA and MICB.
The CC chemokines RANTES, MIP-1α,a n dM I P - 1 β are
produced by activation of macrophages, DCs, T cells, NK
cells, and γδ T cells. These 3 CC chemokines can block the
CCR5 coreceptors and prevent HIV infection in vitro [39].
There is in vivo evidence indicating that raised concen-
trations of CC chemokines downmodulate the cell surface
expression of CCR5. An inverse correlation was established
between the concentration of the 3 CC chemokines and the
proportion of cells expressing CCR5 in macaques immu-
nized with SIV gp120 and p27 [40].
γδ T cells are involved in innate immunity and mucosal
protection; they produce Th1 and Th2 types of cytokines
[41], and they lyse HIV-infected target cells [39]. γδ+ Tc e l l s
also generate antiviral suppressor factors MIP-1α (CCL3),
MIP-1β (CCL-4), and RANTES (CCL-5), which can prevent
SIV infection by binding to and down modulating the CCR5
coreceptors [42].
Defensins have emerged as further components of innate
immunity and may contribute to mucosal protection against
HIV-1 infection especially that of oral mucosa [43].
Finally, important intracellular innate antiviral factors
are represented by APOBEC3G (apolipoprotein B mRNA-
editing, enzyme-catalytic polypeptide-like-3G), TRIM-5
(Tripartite motif-containing protein 5), and tetherin.
APOBEC is packaged into retroviral virions, and it
deaminates viral cytidine to uridine, rendering them non-
functional and inhibiting viral replication. APOBEC3G has
also been found to inhibit HIV by an additional mechanism,
possibly at or prior to the reverse transcription stage of
the viral RNA [44]. This innate mechanism of resistance to
retroviral infection is counteracted by the HIV-1 viral infec-
tivity factor (Vif), which protects the virus by preventing
incorporation of APOBEC3G into virions and by rapidly
inducing its ubiquitination and proteasomal degradation
[44].
Tetherin is a human cellular protein, an IFN-inducible
factor of the innate immune system, which exerts antiviral
activity against HIV-1 and other enveloped viruses by
tethering nascent viral particles to the cell surface, thereby
inhibiting viral release. In HIV-1 infection, the viral pro-
tein U (Vpu) counteracts this antiviral action by down-
modulating tetherin from the cell surface [45].
TRIM5 is a protein encoded in humans by the TRIM5
gene [46]. The alpha isoform of this protein, TRIM5α,i sa
retrovirus restriction factor, which mediates species-speciﬁc
early block to retrovirus infection. TRIM5α was isolated as a
rhesusmacaqueproteinresponsibleforblockinginfectionby
HIV-1. The human version of TRIM5α d o e sn o tt a r g e tH I V -
1,butcaninhibitstrainsofthemurineleukemiavirus(MLV)
as well as equine infectious anemia virus (EIAV) [47].
2.1.2. HCV. While the majority of HCV-infected patients
progress to chronic hepatitis, a small fraction of individuals
are able to clear the virus. Resolution of infection occurs4 Advances in Virology
within the ﬁrst few weeks of infection, suggesting that innate
immunefunctionsmaybecriticalforearlycontrol.Although
all nucleated mammalian cells are able to secrete type I
IFN, the ﬁrst response to HCV infection is thought to be
IFN-β production by infected hepatocytes. In hepatocyes,
recognition of viral motifs at the cell surface is mediated
via TLR3, while the retinoic acid-inducible gene (RIG)-I
acts as a intracellular PAMP receptor for double-stranded
(ds)RNA. These two independent signaling pathways are
suggested to be involved in the activation of interferon
regulatory factor (IRF)-3 and of nuclear factor kappa B (NF-
κB) leading to a transcriptional response that results in the
secretionofIFN-α/β fromtheinfectedcell.ActivationofNF-
κB also induces the expression of proinﬂammatory cytokines
and chemokines that function to amplify the inﬂammatory
responseandfacilitateleucocyterecruitmenttoactinconcert
with IFN-α/β in the host response to HCV [48].
Secreted IFN-α/β acts in both autocrine and paracrine
pathways by binding IFN receptors to trigger activation of
Jak-STAT pathway, leading to induction of IFN-stimulated
genes (ISGs), which are the eﬀectors of the host response to
virus infection [49].
NKcells,whicharepresentingreaternumbersintheliver
than in other organs, contribute to the pathogen-induced
immune responses. Given the diﬃculties in generating eﬃ-
cient adaptive immune responses within the liver, the role
of innate immune mechanisms in the induction of defensive
responses is probably greater than in other tissues [50].
In the inﬂamed HCV-infected liver, activation of innate
immune response induces NK cells to secrete IFN-γ and to
up regulate the expression of the chemokines CXCL9 and
CXCL10. These chemokines bind CCR5 and CXCR3 on liver
inﬁltrating lymphocytes and guide them into the space of
Diss` e and the parenchymal tissue. In addition, NK cells have
a strong cytotoxic potential and are able to rapidly attack
target cells without prior immunization.
2.2. Adaptive Immune Responses. Adaptive immunity refers
to antigen-speciﬁc defense mechanisms, induced during the
chronicphaseofviralinfection,designedtoremoveaspeciﬁc
antigen. There are two major branches of the adaptive
immune responses: humoral immunity and cell-mediated
immunity. The ﬁrst involves the production of antibody
molecules in response to an antigen and is mediated by B-
lymphocytes;thesecondinvolvestheproductionofcytotoxic
T-lymphocytes (CTL), activated macrophages, activated NK
cells,andcytokinesinresponsetoanantigenandismediated
by T-lymphocytes.
2.2.1. HIV. Soon after infection, p24 antigen is detectable in
serum and disappears as the person seroconverts, developing
an antibody response to envelope and core antigens. Most
of the humoral antibody response is directed at the viral
envelope and has little or no neutralizing eﬀect. Neutralizing
antibodies are directed at particular epitopes within the
variable loop regions of gp120 and the pre-fusion complex
of gp41 [51].
CD8+ T cells mediated immunity is the most eﬀective:
upon recognition of viral antigen presented by the epitope-
bearing MHC-I restricted molecule, CD8+ Tc e l l sb e c o m e
activated CTLs, killing the presenting cell by induction of
apoptosis through the release of cytotoxic molecules as
perforin and granzyme A/B, or by activating the Fas-ligand
pathway [52]. CTL responses are detectable throughout the
course of infection, generally being lost only late in the
disease. These responses maintain signiﬁcant pressure on
viral replication and are important for the initial control of
HIV infection and for the determination of viral set point.
In general, the response is narrowly focused in the ﬁrst
weeks to months of infection and then broadens during the
asymptomaticphase,priortodecreasingbothinbreadthand
magnitude late in the disease.
In HIV infection, as in other viral infections, recognition
of viral antigenic peptides activates a CD4+ Th e l p e r
response, expressing a wide range of cytokines (including
IL-2, IFN-γ and tumor necrosis factor (TNF)-β) which co-
ordinate a multi-cellular cell-mediated response against the
invading virus. Activated proliferating HIV-speciﬁc CD4+
T cells are detectable in early infection. The virus infects
activated cells more easily because they express high levels
of the co-receptor CCR5 and also replicates more eﬃciently
in proliferating cells. HIV-speciﬁc CD4+ Tc e l l sa r ep r e f e r -
entially infected early the disease process and subsequently
become diﬃcult to detect. Antigen-speciﬁc CD4+ T cells are
detected at only low levels at other stages of infection, except
insub-populationsofindividualscapableofcontrollingtheir
infection naturally, referred to as long-term non-progressors
(LTNP). Similarly, the majority of HIV-speciﬁc CD4+ Tc e l l s
d e t e c t e da r ea b l et om a k eI F N - γ but not IL-2 [53]. This
lack of appropriate CD4 help likely compromises CD8+ T
cellresponsesandneutralizingantibodyresponses,especially
those to new variants of the virus as they arise. Later in the
disease, also CD4+ T cells recall responses to other pathogens
and antigens are progressively lost, compromising immune
responses to a range of pathogens.
Within the T cell compartment, much interest has been
focused on an altered balance between proinﬂammatory
Th17 cells and regulatory T cells (Tregs) in HIV infection.
Th17 cells are CD4+ T cells that produce IL-17 and play
a central role in host defence against bacterial, fungal,
and viral infections at mucosal surfaces [54]. It has been
recently reported that there is a signiﬁcant loss of Th17 cells
in the gastrointestinal tract of HIV-1 infected individuals
[55]. Because IL-17 serves to maintain the integrity of the
mucosal barrier, loss of Th17 cells may permit the increase
in microbial translocation across the gastrointestinal mucosa
that is observed in pathogenic lentiviral diseases. Recent
studies suggest that the replenishment of Th17 CD4+ Tc e l l s
in the gut mucosa during highly active antiretroviral therapy,
or during nonpathogenic simian immunodeﬁciency virus
infections in the nonhuman primate models, correlates with
better restoration and function of the gut mucosal immune
system [56].
Tregs represent a small subpopulation of T cells involved
in preventing or inhibiting autoimmune and inﬂammatory
disorders [57], but much controversy exists regarding theAdvances in Virology 5
role of Tregs in HIV pathogenesis. One study demonstrated
expansion of Tregs during HIV infection positively cor-
relating with CD4+ T cell activation and rapid disease
progression, indicating a detrimental role of Tregs in the
immune control of HIV infection [58]. Tregs are major
producers of transforming growth factor, (TGF-) α,w h i c h
promotes tissue ﬁbrosis and limits immune reconstitution
[59]. In direct contrast, however, other studies have reported
decreased levels of Tregs in HIV-infected individuals [60],
and in one study, depletion of Tregs in HIV infection was
found to be associated with immune activation [61].
2.2.2. HCV. There is only limited evidence for a signiﬁcant
role for anti-HCV antibody responses in viral clearance,
as recovery from primary infection does not correlate with
HCV-speciﬁc antibody titers or levels of antibodies directed
against the E1 and E2 glycoproteins [62, 63].
The humoral immune response in primary HCV infec-
tion is of low titer and, with exception of responses against
the core protein, the generation of the response is delayed
[64]. HCV-speciﬁc antibodies become detectable in the
serum after the appearance of the cellular immune response
and the subsequent increase in alanine transaminase (ALT).
Another characteristic aspect of the humoral response
against HCV infection is the restriction of antibodies to the
IgG1 subclass, without the usual switching to IgG3 (or
IgG4) subclasses that typically occurs with maturation of an
antiviral humoral response [64]. Interestingly, there may be
an association between the development of IgG2 antibodies
and viral clearance. The IgG2 predominance has been linked
to a Th1 bias in CD4+ T cell responses [65].
DirectevidenceforaprotectiveroleofHCV-speciﬁcanti-
bodies, derives from limited in vivo studies in which chim-
panzees were protected against infection with an HCV
inoculum that was neutralized with HCV-speciﬁc antibodies
in vitro [66]. Thus far, the hypervariable region-1 (HVR-1)
and other regions of the HCV-envelope glycoproteins that
are thought to bind to the putative HCV receptor complex
have been proposed as targets for neutralizing antibodies
[67]. Mutations in the HVR-1 have been associated with
the emergence of the quasispecies leading to escape from
neutralization [68, 69]. This area of the genome is a
region that undergoes a high rates of nucleotide substitution
in acute HCV infection [70] implying that neutralizing
antibodies do provide signiﬁcant selective pressure on the
quasispecies and hence arguing for the importance of this
aspect of the humoral response in clearance.
Despite this circumstantial evidence for a role of neutral-
izingantibodies,individualswithhypogammaglobulinaemia
clearthevirusatasimilarratetothegeneralpopulation[71].
The decrease of viral titer coincides with the appearance
of HCV-speciﬁc T cells and IFN-γ expression in the liver
[72], which suggests that viral clearance is T cell mediated.
These events coincide with the induction of genes that
encode proteins of the adaptive immune responses, such as
MHC class II proteins, immunoproteasome subunits, and
chemokines.
HCV-speciﬁc CD4+ T cells are essential in the generation
of a successful HCV-speciﬁc immune response. At the time
of clinical presentation and ALT elevation, vigorous prolifer-
ation of HCV-speciﬁc CD4+ T cells with concomitant IL-2
and IFN-γ production is readily detectable in the blood of
patients who later recover and clear the infection [73–75].
In contrast, lack of an HCV-speciﬁc CD4+ Tc e l lr e s p o n s e
or failure to maintain it for a suﬃcient time, particularly in
the face of viral mutations or quasi-species shifts, is asso-
ciated with development of persistent infection and chronic
hepatitis [73].
As with CD4+ T cell responses, a strong multispe-
ciﬁc CD8+ T cell response produced early in infection is
associated with viral clearance [76–80]. CD8+ Tc e l lr e s -
ponses directed against multiple epitopes spanning the HCV
polyprotein were seen in chimpanzees that resolved infec-
tion, whereas animals that developed chronic infection gen-
erated narrow responses [80].
During acute HCV infection, CD8+ T cells appear func-
tionally impaired, with reduced proliferation, IFN-γ pro-
duction, and cytotoxicity [76, 81, 82] and increased levels of
programmed death (PD)-1 [83]. However, the dysfunction
of HCV-speciﬁc CD8+ T cells resolves, and IL-7 receptor α-
positive (i.e., CD127+)m e m o r yC D 8 + Tc e l l sb e c o m e
detectable, as soon as HCV-speciﬁc CD4+ T cell responses
develop and the HCV titer decreases [76, 82, 84].
3. Mechanisms of Immune Evasion
To replicate and spread successfully, viruses have evolved a
number of strategies to evade host defenses. These include
escape from T-cell recognition, resistance to immunological
eﬀectors functions, and active subversion of the immune
response. Because of the high replication rate and the lack
of proofreading capacity of both HIV and HCV DNA poly-
merases, the sequence and immunogenicity of the main viral
populations can rapidly change and provide means to escape
from emerging humoral and cellular immune responses.
3.1. HIV. The envelope of HIV is the primary target for
humoral responses, and the virus has developed numerous
mechanismsforavoidingtheeﬀectofneutralizingantibodies
that are primarily directed towards envelope protein epi-
topes. Firstly, many of the neutralizing epitopes are cryptic,
hidden within the protein structure of the molecule, and
exposed only transiently. To be eﬀective at these sites,
antibodies require a high aﬃnity to compete with natural
ligands. Secondly, major neutralizing epitopes are protected
by protein glycans, which form a shield to provide steric
hindrance against anti-gp120 interaction [85]. Finally, the
glycoproteins are highly mutable, conferring upon virus the
ability to mutate rapidly away from eﬀective neutralizing
antibodies with minimal cost to viral ﬁtness. Resistance to
antibodies by point mutation on the V2/V3 loop and N-
linked carbohydrate glycans on gp120 has been indicated as
hindering antibody neutralization [86].6 Advances in Virology
Similarly, the virus has developed multiple mechanisms
to avoid recognition by CD8+ CTL; these include both
mutational and non-mutational mechanisms. Viral proteins,
including Nef, Tat, and Vpu, interfere with antigen presenta-
tion by downregulating the expression of MHC-1 molecules
on the surface of these cells [87]. Most of these act at a
post-transcriptional site. Conversely, selective upregulation
of HLA-C and E by Nef may protect infected cells from NK
cell attack. Virus can mutate at targeted epitopes to avoid
MHC restricted recognition, by decreasing binding aﬃnity
of the epitope to the presenting protein MHC-1 [88, 89].
Alternatively, mutations may alter the recognition of antigen
peptide by a particular TCR, either resulting in no activation
of the T cell or delivering an antagonistic signal to the T cell,
preventing normal activation [90]. Mutations may also alter
the chemistry of antigen processing through the proteasome
and peptide-loading complex, so that peptide is no longer
presented. Recent studies have indicated the expression of
cryptic epitopes from proteins expressed through alternative
reading frames.
Successful elimination of the virus requires a robust
innate immune response and eﬃcient priming of adaptive
immunity. DC, are central in both these process. Evidences
indicate that DC function is impaired during HIV-1 infec-
tion, contributing to a lack of eﬀective antiviral adaptive
immunity. This is either due to direct viral interactions
with DCs or a result of indirect mechanisms, such as the
production of IL-10 by monocytes during infection. pDCs
activated by HIV-1 produce type I IFNs, which, in addition
to inhibiting viral replication, may contribute to bystander
CD4+ T cell death. Furthermore, evidence shows that pDCs
produce T cell-attracting chemokines, which may facilitate
viral spread by providing a source of new T cells for HIV to
infect. Finally, HIV-exposed pDCs prime regulatory T cells,
which could impair mDC function and block eﬀector T cell
activity, further blunting adaptive immunity [91, 92].
3.2. HCV. HCV, after the initial interaction with the host
immune system, uses several mechanisms to nullify the
selective immunological pressure during the later phases of
infection, including the alteration of its antigenic epitopes to
escape immune surveillance. The human immune responses
to HCV and the countermeasures of the virus are directly
relevant to antiviral therapy given the main use of IFN-α in
standard treatment. The best understood immune-evasive
strategiesincludeinhibitionofproteinkinaseR(PKR)bythe
viral NS5A and E2 proteins [93], cleavage of cellular signal
transduction molecules downstream of RIG-1 and TLR3 by
the NS3/4A protein, and altering IL-12 production through
secretion of the core protein.
Another evading strategy of HCV targets TLR7 expres-
sion, mRNA stability, and signalling. Recent studies have
identiﬁed a signiﬁcantly decreased TLR7 expression in the
presence of HCV, both in vitro and in vivo.I tw a ss u g g e s t e d
that HCV may directly interfere with the transcriptional reg-
ulation of TLR7 mRNA. Despite decreased TLR7 expression
in HCV-replicating cells, enhanced activation of IRF-7 was
observed [94].
Many researchers have explored the hypothesis that the
failure of HCV-infected individuals to mount an eﬀective T
cell response, thus developing chronic HCV infection, was
due to the impairment of DC function [95, 96]. However,
in spite of extensive studies, there is little overall consensus.
The majority of studies observed decreased frequencies of
both mDC and pDC during chronic infection [97–102]. It
has been shown that the numbers of mDC and pDC in the
liver of patients with chronic HCV infection were markedly
increased, as compared to controls. Thus, it is diﬃcult to
determine if accumulation of DCs in the liver is casually
related to the decrease of DC number in peripheral blood.
There is less agreement about the eﬀect of chronic HCV
infection on the function of circulating mDC and pDC.
mDC from patients with chronic HCV infection have been
reported to be ineﬃcient at driving na¨ ıve T cell proliferation
inallogeneicmixed-lymphocytereaction(MLR)[97,98,101,
103]. However, in other studies, the ability to induce T cell
proliferation in MLR or antigen-speciﬁc T cell responses
was intact in DC obtained from patients with HCV [102,
104, 105]. A common ﬁnding in many studies is that IL-
12 secretion by mDC is defective in cells obtained from
patients with chronic HCV infection, while secretion of IL-
10 increased as compared to healthy individuals [98, 99, 101,
106].
Many studies also described the impaired function of
pDC in patients with HCV, resulting in abnormal IFN-
α secretion in chronic HCV infection [106].
The impairment of DC function may not only inﬂuence
T cell priming but may also preclude productive cross-
talk between NK and DC. The abnormality of the NKG2A-
expressing subpopulation also aﬀects DC/NK cross-talk
during chronic HCV infection [50].
Cross-sectional studies have indicated that NK cells
are perturbed in chronic HCV infection. There may be a
decrease in the number of circulating NK cells and skewing
of NK cell subset distribution toward increased numbers of
thecytokine-producingCD56bright population,relativetothe
cytotoxicCD56dim subpopulation.Inaddition,recentstudies
have shown that binding of recombinant HCV E2 protein
and crosslinking of CD81 inhibit NK cell functions, such as
cytotoxicity, proliferation, and IFN-γ and TNF-α secretion
in vitro [50, 107–109].
4. Polymorphisms in Host Response Genes
4.1.HIV. Epidemiologicalstudiesofgeneticpolymorphisms
in human populations have enabled new ways to understand
antiviral response and immune activation during HIV infec-
tion. The natural course of HIV infection is characterized
by considerable variations among infected individuals, and
is related to both viral and host factors, including genetic
diﬀerences.
One of the ﬁrst studies addressing this question was
the description of almost complete protection from HIV
infection conferred by homozygosity of a 32 base deletion
in CCR5 (CCR5-l32) or a mutation in CCR2 (CCR2-64I)
[110]. They provide strong protection and are found more
frequently in LTNP than in rapid progressors.Advances in Virology 7
Moreover, certain HLA alleles are associated with control
of virus replication and slower progression to AIDS [111].
For virus replication control, a strong CTL response is
crucial. CTLs are activated by binding to antigenic peptides
presented by HLA, initiating the immune response. Many
studies report the eﬀect of HLA polymorphisms on the
progression of AIDS [112, 113]. Many HLA alleles have
been correlated with rapid disease progression, as HLA-A24,
-A29, -B35, -C4, -DR1, and -DR3, whereas patients carrying
HLA-B14, -B27, -B57, -C8, or -DR6 appear to develop AIDS
more slowly [114, 115]. It is known that LTNPs remain
asyntomatic and clinically healthy for more than 10 years
without therapy [116, 117]. A number of studies [118–120]
have shown a higher frequency of the HLA-B27 and HLA-
B57 alleles in this group of patients, suggesting also a role of
these alleles in the pathogenesis of HIV [111]. It has been
shown that CD8+ T cells of individuals expressing HLA-
B27 or -B57, targeted a deﬁned and highly conserved region
within the HIV-1 p24 Gag (amino acids 240 to 272) early
in infection, and responses against this region contributed
over 35% to the total HIV-1-speciﬁc T cell responses in these
individuals. In contrast, this region was rarely recognized
in individuals expressing HLA alleles associated with rapid
disease progression [121].
The HLA genotyping could help identifying those
patients with either a mild or aggressive course of their
natural HIV-1 infection. This might inﬂuence the timing
to start HIV therapy and allow a risk stratiﬁcation that
could be relevant in countries with limited access to antiviral
drugs. Moreover, under antiretroviral therapy, HLA type
may inﬂuence the risk of developing drug-resistant viruses,
and therefore address the choice of drug regimens in na¨ ıve
patients. Finally, since HLA loci vary by ethnic groups and
regions, it may aﬀect the response to speciﬁc vaccines in
diﬀerent parts of the world.
Recently, the association between polymorphisms in the
inﬂammasome component NLRP3 and susceptibility to HIV
infection has been demonstrated and adds to other studies
linking inﬂammasome activation and IL-1/IL-18 production
with HIV pathogenesis [122].
For the association of TLRs polymorphisms and HIV-
induced inﬂammation, somewhat more insight exists. One
study reported an association between two single nucleotide
polymorphisms (SNP)s in TLR9 and rapid HIV progression
as measured by CD4+ T cell decline [123], although the
investigators did not evaluate the precise eﬀect of these
SNPs on TLR9 signalling. In contrast, a diﬀerent TLR9
polymorphism has been linked to slow disease progression
and found less frequently among individuals with high viral
setpoint[124].Inaddition,afrequentfunctionalTLR7poly-
morphism resulting in signiﬁcantly less IFN-α production
has been associated with accelerated disease progression and
may also be associated with increased HIV susceptibility,
since this mutation was present more frequently in patients
than in controls [125]. The importance of TLR7 signalling
was further supported by a recent article demonstrating
sex diﬀerences in the TLR7-mediated response of pDCs to
HIV: pDCs from women produce markedly more IFN-α in
response to HIV-derived TLR7/8 ligands than pDCs from
men, resulting in a higher degree of immune activation in
women for a given viral load [126]. At the genetic level,
this may be explained by the fact that TLR7 is X-linked
and therefore women may have higher expression of this
receptor due to unbalanced X-inactivation. Clinically, the
more robust IFN-α response in women is translated into
women exhibiting lower viral loads early in infection but
progressing faster to AIDS for any given viral load [127].
Taken together, these studies support the idea of type I
IFN having dual functions, including antiviral activities and
immune activation.
4.2.HCV. CombinationtherapywithPeg-IFNplusribavirin
is the standard treatment for patients with chronic HCV
infection [128]. However, it eradicates HCV in only about
half of the patients infected with genotype 1. The outcome
of IFN-based therapy for HCV is dependent on the genetic
systems of both the human host and the virus. Host genetic
factors that inﬂuence the outcome of therapy include gender,
race, and variation in genes of the immune system.
The dominant role of the immune-modulator IFN-α in
treating HCV infection has driven an extensive search for
genetic associations between components of the immune
system and outcome of therapy [129–131].
To date, the most prominent human genetic associations
with outcome of therapy are SNPs within the IL28B gene.
The strongest association was found for SNP rs12979860,
located about 3kb upstream of the IL28B coding region.
Patients with a CC genotype at this SNP were more than
twice as likely to achieve sustained virologic response (SVR)
as patients with a CT or TT genotype [132]. Suppiah et al.
[133] estimated that the cumulative eﬀect of the favorable
allele at the IL28B locus is to increase SVR by 32% relative
to a population in which the allele is absent. The favorable
association of the CC genotype was found in patients of both
European and African-American descent, and diﬀerential
prevalence of the CC genotype explained approximately
half of the twofold poorer response rate to treatment
found in African Americans. Several reports have associated
failure of response also with the presence of SNP rs8099917
and rs12980275. All these associations were shown to be
signiﬁcant for genotypes 1 and 4 but not for genotypes 2 and
3[ 134, 135].
The IL28B gene encodes the type 3 IFN, namely,
IFNλ that has been shown to inhibit HCV replication; so the
variations in the IL28B gene mutations presumably aﬀect the
eﬃcacy of the innate immune response against HCV during
therapy [134].
Interestingly, the pretreatment expression levels of genes
involved in IFN-stimulated genes (ISGs) have been found to
berelatedtotreatmentoutcome.ThealleleOASLrs12819210
constitutes an important independent factor that is sig-
niﬁcantly associated with SVR in peg-IFN-plus-ribavirin
treatment, notably improving the predictive value of IL-28B
rs12979860. In addition to OASL and IL-28B, the IFIT1
rs304478 A/A genotype favors a better therapy outcome,
especially in patients with HCV-1 [136].8 Advances in Virology
The most common associations with clearance after pri-
maryinfectionhasbeenwiththec lassIIalleles,DQB1 ∗0301,
and DRB1∗1101 which are in close linkage disequilibrium.
It has been demonstrated that immunodominant HCV
epitopes are presented by DRB1∗1101 [137] and that T
cell lines recognize HCV peptides presented by DQB1∗0301
[138]. Similarly, another allele that has been associated with
HCV clearance, DRB1∗0101, was associated with a greater
magnitude and broader range of epitope responses in an
HCV-speciﬁc T cell proliferation assay [139].
By contrast, only very few of class I HLA allele associ-
ations have been described in association with clearance of
HCV viremia. KIR2DL3 and its ligand, HLA-C1 has been
associated with an increased likelihood of spontaneous and
treatment-induced HCV clearance [140–142]. It has been
postulated that this gene combination is protective because
the KIR2DL3 binds HLA-C with a lower avidity than other
inhibitory KIR and thus NK cells expressing this speciﬁc
inhibitory receptor have a lower threshold for activation
[143, 144].
NK cells are also inhibited by the heterodimeric receptor
CD94:NKG2A, which has the oligomorphic MHC class I
molecule HLA-E as ligand. In a genetic study, homozygosity
fortheHLA-ER allelehasbeenshowntobeprotectiveagainst
chronic infection with HCV genotypes 2 and 3 [145]. This
protective eﬀect was thought to be due to an eﬀect on HLA-
E-restricted T cells, although the HLA-ER allele may have a
lower aﬃnity for peptides and hence be expressed at lower
levels.Thiscould,therefore,leadtolessinhibitionofNKcells
via the CD94:NKG2A receptor [146]. The presence of HLA-
B27 allele has also been associated with viral clearance [147]
and a functional mechanism for this eﬀect has been reported
with the recognition of an HLA-B27 restricted CD8 epitope
[148].
Genetic associations with outcome of therapy have also
been reported for the genes encoding KIR2DL5, IL-6, IL-
12B, IL-18, CCL5, TNF-α,I F N - γ, osteopontin, GNB3, and
CTLA4. Several SNPs of TLR, relevant adaptor molecules
and cytokines mediated by TLR signaling can aﬀect various
clinical outcomes in Caucasian patients with chronic HCV.
However, the role of these polymorphisms in acute infection
has not been elucidated [149]. However, other studies
have failed to ﬁnd associations with many of these genes.
The inconsistencies in these data appear to be due to
diﬀerences among the studies in racial make-up and HIV co-
infection status of the cohorts, the deﬁnition of therapeutic
response, the therapy employed (IFN-α monotherapy, IFN
plusribavirin,orpegylatedIFNplusribavirin),andtheHCV
genotype infecting the study participants.
Other immunogenetic polymorphism have recently been
reported to inﬂuence outcome of HCV infection such as
polymorphisms of the promoter region of the IL-10 gene
with the IL-10-592 AA genotype associated with self limiting
infection, and the IL-10-1082GG genotype associated with
persistent infection [150, 151]. Another study demonstrated
an association between the IL-10 ATA haplotype (IL-10-
1082A, -819T, -592A) and spontaneous HCV clearance
[151]. The authors postulated that the reduced production
of IL-10 associated with this haplotype may result in
a Th1-polarized CD4+T cell response, which may be asso-
ciated with enhanced viral elimination.
The presence of polymorphisms of the TGF-β1g e n e
promoter that reduce expression of TGF-β1 is also associated
with increased rates of clearance of HCV infection [152].
Simultaneous genotyping for all these SNPs could be a
useful tool for individualizing antiviral therapy for chronic
hepatitis C.
5. Conclusions
HIV and HCV share many characteristics: both are RNA
virusesandhavesimilarblood-to-bloodtransmissionroutes.
Despite these viruses markedly diﬀer in their virological pro-
perties and in their pathogenesis, they share many common
features in their immune escape and survival strategy.
In the last years, much eﬀort has been done on the
study of the AIDS pathogenesis and on the development of
eﬃcient treatment strategies and a fatal infection has been
transformed in a potentially chronic pathology. Much of this
knowledge is now being transferred in the HCV research
ﬁeld, especially in the development of new drugs, although
a big diﬀerence still remains between the outcome of the two
infections, being HCV eradicable after treatment, whereas
HIV eradication remains at present unachievable due to the
establishment of reservoirs.
In the era of eﬀective HIV therapy, chronic HCV
infection is a leading cause of liver disease and mortality in
HIV-infected patients. Whereas treatment of HIV with ART
appears to slow the progression of liver disease, co-infected
patients remain at greater risk for HCV disease progression
than patients with HCV mono-infection. Accordingly, eﬀec-
tive HCV treatment is a priority in this population.
The knowledge of the immunogenetic background may
enable to calculate a composite genetic risk, which will be of
increasing importance in the tailored management of HIV
and HCV mono-infected or co-infected patients. Obtaining
a molecular understanding of the mechanisms by which the
genetic associations modulate the outcome of therapy would
substantially improve therapy. In addition, the immunologic
characterization of the patients could be useful to speculate
on the need for immunotherapy for these patients.
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